At a glance
ClinicalIndex Comparison RecordN/ACompleted· 227 enrolled
Drug / intervention
Sangvia® Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Randomized, Controlled Trial of Retransfusion of Intra-operatively Collected Filtered Whole Blood in Total Hip Surgery
In Brief
A clinical study evaluating Sangvia® System for Arthroplasty, Replacement, Hip and 2 related conditions. Completed, enrolled 227 participants across 6 sites in 4 countries.
Detailed Summary
The study is a prospective, controlled, randomised and assessor blind study that investigate if the need for bank blood transfusion could be reduced in patients, undergoing primary or revision total hip replacement surgery, who receive their own blood back with the medical device Sangvia. A comparison in need for bank blood will be made between patients that either receive their own blood back or not.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustria, Netherlands, Norway, Spain
Collaborators--
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 2009
Enrollment StartMay 2009
Primary CompletionJun 2010
TodayJul 2026
First PostedJan 14, 2009
Enrollment StartMay 1, 2009
Primary CompletionJun 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 17.5 years ago
Interventions
Sangvia® Systemdevice
Sangvia® Intra- and Post-op System